Mind The Gap: Different Views Of Success May Drive Large Differences In Estimates Of Pharma Value

The success rates of late-stage molecules may prove to be higher than current analyst estimates; historical data suggests the biopharma industry has been fairly resilient in its ability to deliver its R&D pipeline while adapting to challenges.